What is the 52 Week High and Low of Aurobindo Pharma Share Price?

The 52 week high and low prices of Aurobindo Pharma share price is 1636.8 & 1016.1. They indicate price extremes, trading ranges, volatility measures, potential support/resistance, and price momentum.

Aurobindo Pharma Share price

Q: How to buy Aurobindo Pharma Share at Choice?

To buy Aurobindo Pharma stocks , log in to your Choice trading account. If you don’t have one, open a Choice Demat account. Then, add funds, search for Aurobindo Pharma, choose your preferred order type, and place the trade.

AUROPHARMA

Healthcare Large Cap

1587.4

30.00 (1.93%)

NSE

BSE

Last updated on 9 Jul, 2026 | 15:49 IST

BUYSELL

Today's High

1602.80

Today's Low

1550.10

52 Week Low

1016.10

52 Week High

1636.80

Aurobindo Pharma share price chart

ChartIQ

TradingView

Aurobindo Pharma Share Key Metrics

Volume

8.04 L

Market Cap

91335.49 CR

LTQ@LTP

1@1587.40

ATP

1588.19

Var Margin

14.57 %

Circuit Range

1401.7-1713.1

Delivery %

36.28 %

Value

127.62 CR

ASM/GSM

No

Market Lot

1

Summary

AUROPHARMA stock price is ₹1587.4 as of 9 Jul, 2026. The stock intraday movement has stayed between ₹1550.10 and ₹1602.80, while Aurobindo Pharma share price 52 week high low is ₹1016.10 & ₹1636.80.

In terms of trading activity, AUROPHARMA share price has recorded a volume of 8,03,529 shares. The Aurobindo Pharma has a market cap of ₹575377895. The stock’s Average Traded Price (ATP) stands at ₹1588.19, while the Last Traded Quantity at Last Traded Price (LTQ@LTP) is 1 @ ₹1587.40.

The Aurobindo Pharma upper circuit limit is ₹1713.10 & The Aurobindo Pharma lower circuit limit is ₹1401.70, with a Value of ₹127.62 CR. The Delivery Percentage for the day is 36.28%.

Additionally, the share currently falls under the No framework, and trades with a market lot size of ₹1.

Aurobindo Pharma Fundamentals

P/E Ratio

25.56

P/B Ratio

2.36

Div. Yield

0.26

Sector P/E

68.55

Sector P/B

3.18

Sec. Div. Yield

0.53

Aurobindo Pharma Resistance and Support

Pivot 1573.63

Resistance

First Resistance

1595.16

Second Resistance

1632.93

Third Resistance

1654.46

Support

First Support

1535.86

Second Support

1514.33

Third Support

1476.56

Aurobindo Pharma Futures & Options

Aurobindo Pharma Ltd Share Price

1587.4

30 (1.93%)

Aurobindo Pharma Option Chain

View Price, OI, Greeks & More...

View All

28JUL26

1588.90

29.20 (1.87%)

25AUG26

1598.40

32.50 (2.08%)

29SEP26

1608.00

33.20 (2.11%)

AUROPHARMA|28JUL26 CE 1580.00

42.00 11.5 (37.7%)

AUROPHARMA|28JUL26 PE 1600.00

41.3 -20.8 (-33.49%)

Aurobindo Pharma Shareholding Pattern

2016-17
2018-19
2019-20
2020-21
2021-22
2022-23
2023-24
2024-25
2025-26
2026-27

Total Promoters

Segment

Percent

Total Promoters

51.82%

Mutual Fund

17.79%

Insurance

5%

Foreign Institutional Investors

15.24%

Domestic Institutional Investors

3.08%

Retail

7.08%

Others

-0.01%

Total Promoters

MAR '26

51.82%

Aurobindo Pharma Corporate Actions

Date	Agenda
2026-05-21	Audited Results
2026-04-06	Buy Back of Shares
2026-02-09	Quarterly Results
2025-11-05	Quarterly Results
2025-08-04	Quarterly Results & Interim Dividend
2025-05-26	Audited Results
2025-02-06	Quarterly Results

Aurobindo Pharma News

Aurobindo Pharma Ltd - 524804 - Completion Of Transfer Of Company'S Domestic Branded Generic Pharmaceutical Formulations Products Business To Auropharm Limited, A Wholly Owned Subsidiary Of The Company

Aurobindo Pharma completed the transfer of its domestic branded generic pharmaceutical formulations products business to its wholly-owned subsidiary, Auropharm Limited, effective July 1, 2026. This reorganization consolidates operations under a specific group entity.

Jul 02 2026 10:38:56

Aurobindo Pharma Ltd - 524804 - Announcement under Regulation 30 (LODR)-Updates on Acquisition

Aurobindo Pharma USA Inc. (APUSA), a wholly-owned subsidiary, has completed the acquisition of Lannett Company, Inc., USA. This move strengthens APUSA's access to critical medications and expands its operational capabilities by integrating over 400 Lannett employees.

Jun 30 2026 09:54:23

Aurobindo Pharma Ltd - 524804 - Completion Of US FDA Inspection At Auroactive Pharma Private Limited, A Wholly Owned Subsidiary Of The Company.

Aurobindo Pharma's wholly owned subsidiary, Auroactive Pharma Private Limited, received 2 observations from the US FDA after an inspection at its Srikakulam API and Pharmaceutical Formulation Intermediates manufacturing facility in Srikakulam, Andhra Pradesh. The company will respond within the stipulated time.

Jun 27 2026 10:35:47

Aurobindo Pharma Ltd - 524804 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Aurobindo Pharma USA, a subsidiary, received FTC approval to acquire Lannett Company LLC for $250 million. This acquisition will enhance its generic product offerings and add a US-based manufacturing facility, strengthening domestic production capacity.

Jun 22 2026 07:27:51

Aurobindo Pharma Ltd - 524804 - Completion Of US FDA Pre-Approval Inspection (PAI) At Eugia Steriles Private Limited, A 100% Stepdown Subsidiary Of The Company

Aurobindo Pharma's 100% stepdown subsidiary, Eugia Steriles Private Limited, underwent a US FDA Pre-Approval Inspection (PAI) that concluded with 5 observations. The company will address these observations within the stipulated timeframe.

Jun 19 2026 21:10:08

Aurobindo Pharma Ltd - 524804 - Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.

Aurobindo Pharma USA Inc. obtained the necessary approval from the US Federal Trade Commission (FTC) for its 100% acquisition of Lannett Company LLC from LANNETT SELLER HOLDCO, INC. The transaction is expected to close before the end of this month.

Jun 19 2026 08:24:32

Aurobindo Pharma Ltd - 524804 - Classification Of US FDA Inspection At Unit-III Of Eugia Pharma Specialities Limited, Pashamylaram (Our Wholly Owned Subsidiary) As OAI

Aurobindo Pharma's wholly owned subsidiary, Eugia Pharma Specialities, received an Official Action Indicated (OAI) classification from the US FDA for its Unit-III formulation manufacturing facility. The inspection, conducted from January 27 to February 06, 2026, concluded with 11 observations.

Jun 12 2026 18:17:06

Name	Position
Mangalam Ramasubramanian Kumar	Chairman
K Nityananda Reddy	Vice Chairman & Managing Director

Aurobindo Pharma Similar Stocks

Dr. Reddy's Laboratories Ltd.

1269.50

-79.50 (5.89%)

Max Healthcare Institute Ltd.

1101.30

16.50 (1.52%)

Mankind Pharma Ltd.

2532.00

40.80 (1.64%)

Lenskart Solutions Ltd.

545.95

9.40 (1.75%)

Laurus Labs Ltd.

1507.40

38.20 (2.60%)

Fortis Healthcare Ltd.

951.45

7.70 (0.82%)

Alkem Laboratories Ltd.

5648.50

42.50 (0.76%)

Biocon Ltd.

403.55

6.50 (1.64%)

Glenmark Pharmaceuticals Ltd.

2267.20

43.50 (1.96%)

Aurobindo Pharma FAQs

The Buying Price of Aurobindo Pharma share is 1587.4 For live prices and instant trading, you can log in to your Choice trading account or open a Free Demat account with Choice.

To buy Aurobindo Pharma stocks, log in to your Choice trading account. If you don’t have one, open a Choice Demat account. Then, add funds, search for Aurobindo Pharma, choose your preferred order type, and place the trade.

The Price-to-earnings (P/E) ratio of Aurobindo Pharma shares is 25.56. You can compare it with the sector average for relative valuation.

The Price to Book (P/B) ratio Aurobindo Pharma shares is 2.36. Useful to assess the stock's value relative to its book value.

To assess Aurobindo Pharma’s valuation compare Sector P/E, P/B which are 68.55 & 3.18 with sector averages, along with growth rates and financial metrics.

The Market Cap of Aurobindo Pharma is 91335.49 CR. It indicates the company's size category and trading liquidity.

The 52 week high and low prices of Aurobindo Pharma share price is 1636.80 & 1016.10. They indicate price extremes, trading ranges, volatility measures, potential support/resistance, and price momentum.

Aurobindo Pharma belongs to the Healthcare sector.